Anti-PD-1 and anti-PD-L1 drugs treatment-related adverse events for patients with cancer: Protocol for an overview of systematic reviews with meta-analyses

BACKGROUND: Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) drugs treatment-related adverse events (AEs) are not uniform based on current study for patients with cancer. The study aimed to provide a complete toxicity profile and toxicity spectrum for anti-PD-1 and...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jing, Liu, Ming, Wang, JianShu, Liu, Zhao, Xue, JinXu, Wang, JianCheng, Jia, JunHai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635244/
https://www.ncbi.nlm.nih.gov/pubmed/31277179
http://dx.doi.org/10.1097/MD.0000000000016324

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6635244/
https://www.ncbi.nlm.nih.gov/pubmed/31277179
http://dx.doi.org/10.1097/MD.0000000000016324

Ejemplares similares